Compass Wealth Management LLC Sells 11,454 Shares of Novartis AG $NVS

Compass Wealth Management LLC trimmed its position in shares of Novartis AG (NYSE:NVS) by 86.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,868 shares of the company’s stock after selling 11,454 shares during the period. Compass Wealth Management LLC’s holdings in Novartis were worth $240,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Keybank National Association OH boosted its holdings in Novartis by 13.2% in the 2nd quarter. Keybank National Association OH now owns 49,377 shares of the company’s stock worth $5,975,000 after buying an additional 5,742 shares during the period. Lockheed Martin Investment Management Co. grew its position in shares of Novartis by 15.6% in the third quarter. Lockheed Martin Investment Management Co. now owns 85,200 shares of the company’s stock valued at $10,926,000 after purchasing an additional 11,500 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Novartis by 5.5% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 132,536 shares of the company’s stock valued at $17,001,000 after purchasing an additional 6,924 shares during the period. Geneos Wealth Management Inc. lifted its holdings in Novartis by 27.7% during the 3rd quarter. Geneos Wealth Management Inc. now owns 64,760 shares of the company’s stock worth $8,305,000 after purchasing an additional 14,032 shares in the last quarter. Finally, HM Payson & Co. lifted its holdings in Novartis by 306.6% during the 3rd quarter. HM Payson & Co. now owns 13,262 shares of the company’s stock worth $1,701,000 after purchasing an additional 10,000 shares in the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Trading Up 2.0%

Shares of Novartis stock opened at $152.08 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.88 and a quick ratio of 0.68. Novartis AG has a 1 year low of $97.71 and a 1 year high of $152.48. The firm has a market cap of $321.27 billion, a PE ratio of 20.78, a PEG ratio of 1.94 and a beta of 0.51. The company has a 50 day simple moving average of $137.06 and a two-hundred day simple moving average of $129.08.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $2.25 earnings per share for the quarter, missing the consensus estimate of $2.26 by ($0.01). Novartis had a net margin of 26.49% and a return on equity of 41.21%. The company had revenue of $14.36 billion for the quarter, compared to analysts’ expectations of $13.70 billion. During the same quarter last year, the business posted $2.06 EPS. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. Analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NVS has been the subject of a number of recent analyst reports. Barclays raised Novartis from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research note on Monday, December 29th. Cfra set a $126.00 target price on shares of Novartis and gave the stock a “hold” rating in a research note on Wednesday, October 29th. HC Wainwright downgraded shares of Novartis to a “neutral” rating in a report on Monday, October 27th. Finally, Wall Street Zen raised shares of Novartis from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $119.75.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.